Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.

Alberto Bianchi; Markus von Deimling; Maximilian Pallauf; Takafumi Yanagisawa; Tatsushi Kawada; Hadi Mostafaei; Fahad Quhal; Ekaterina Laukhtina; Pawel Rajwa; Muhammad Majdoub; Reza Sari Motlagh; Benjamin Pradere; Pierre I Karakiewicz; Maria Angela Cerruto; Alessandro Antonelli; Shahrokh F Shariat

doi:10.1080/14656566.2022.2150966

Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.

Alberto Bianchi
, Markus von Deimling
, Maximilian Pallauf (Co-author)
, Takafumi Yanagisawa
, Tatsushi Kawada
, Hadi Mostafaei
, Fahad Quhal
, Ekaterina Laukhtina
, Pawel Rajwa
, Muhammad Majdoub
, Reza Sari Motlagh
, Benjamin Pradere
, Pierre I Karakiewicz
, Maria Angela Cerruto
, Alessandro Antonelli
, Shahrokh F Shariat

Department of Urology and Andrology

Research output: Contribution to journal › Review article › peer-review

4 Citations (Web of Science)

Original language	English
Pages (from-to)	177-195
Number of pages	19
Journal	EXPERT OPINON ON PHARMACOTHERAPY
Volume	24
Issue number	2
Early online date	29 Nov 2022
DOIs	https://doi.org/10.1080/14656566.2022.2150966
Publication status	Published - Feb 2023

Keywords

TRANSITIONAL-CELL-CARCINOMA
INVASIVE BLADDER-CANCER
PHASE-III TRIAL
HISTONE DEACETYLASE INHIBITORS
CISPLATIN-INELIGIBLE PATIENTS
GEMCITABINE PLUS CISPLATIN
RADICAL CYSTECTOMY
OPEN-LABEL
SINGLE-ARM
NEOADJUVANT CHEMOTHERAPY
Humans
Antineoplastic Agents/therapeutic use
Urinary Bladder Neoplasms/drug therapy
Carcinoma, Transitional Cell/drug therapy
Immunotherapy
Quality of Life

Access to Document

10.1080/14656566.2022.2150966

Cite this

Bianchi, A., von Deimling, M., Pallauf, M., Yanagisawa, T., Kawada, T., Mostafaei, H., Quhal, F., Laukhtina, E., Rajwa, P., Majdoub, M., Motlagh, R. S., Pradere, B., Karakiewicz, P. I., Cerruto, M. A., Antonelli, A., & Shariat, S. F. (2023). Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. EXPERT OPINON ON PHARMACOTHERAPY, 24(2), 177-195. https://doi.org/10.1080/14656566.2022.2150966

@article{0a0fbd9462e54be0b34672b11eda1e8e,

title = "Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.",

keywords = "TRANSITIONAL-CELL-CARCINOMA, INVASIVE BLADDER-CANCER, PHASE-III TRIAL, HISTONE DEACETYLASE INHIBITORS, CISPLATIN-INELIGIBLE PATIENTS, GEMCITABINE PLUS CISPLATIN, RADICAL CYSTECTOMY, OPEN-LABEL, SINGLE-ARM, NEOADJUVANT CHEMOTHERAPY, Humans, Antineoplastic Agents/therapeutic use, Urinary Bladder Neoplasms/drug therapy, Carcinoma, Transitional Cell/drug therapy, Immunotherapy, Quality of Life",

author = "Alberto Bianchi and \{von Deimling\}, Markus and Maximilian Pallauf and Takafumi Yanagisawa and Tatsushi Kawada and Hadi Mostafaei and Fahad Quhal and Ekaterina Laukhtina and Pawel Rajwa and Muhammad Majdoub and Motlagh, \{Reza Sari\} and Benjamin Pradere and Karakiewicz, \{Pierre I\} and Cerruto, \{Maria Angela\} and Alessandro Antonelli and Shariat, \{Shahrokh F\}",

note = "Pallauf: Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria",

year = "2023",

month = feb,

doi = "10.1080/14656566.2022.2150966",

language = "English",

volume = "24",

pages = "177--195",

journal = "EXPERT OPINON ON PHARMACOTHERAPY",

issn = "1465-6566",

publisher = "Taylor \& Francis ",

number = "2",

}

Bianchi, A, von Deimling, M, Pallauf, M, Yanagisawa, T, Kawada, T, Mostafaei, H, Quhal, F, Laukhtina, E, Rajwa, P, Majdoub, M, Motlagh, RS, Pradere, B, Karakiewicz, PI, Cerruto, MA, Antonelli, A & Shariat, SF 2023, 'Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.', EXPERT OPINON ON PHARMACOTHERAPY, vol. 24, no. 2, pp. 177-195. https://doi.org/10.1080/14656566.2022.2150966

TY - JOUR

T1 - Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.

AU - Bianchi, Alberto

AU - von Deimling, Markus

AU - Pallauf, Maximilian

AU - Yanagisawa, Takafumi

AU - Kawada, Tatsushi

AU - Mostafaei, Hadi

AU - Quhal, Fahad

AU - Laukhtina, Ekaterina

AU - Rajwa, Pawel

AU - Majdoub, Muhammad

AU - Motlagh, Reza Sari

AU - Pradere, Benjamin

AU - Karakiewicz, Pierre I

AU - Cerruto, Maria Angela

AU - Antonelli, Alessandro

AU - Shariat, Shahrokh F

N1 - Pallauf: Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria

PY - 2023/2

Y1 - 2023/2

KW - TRANSITIONAL-CELL-CARCINOMA

KW - INVASIVE BLADDER-CANCER

KW - PHASE-III TRIAL

KW - HISTONE DEACETYLASE INHIBITORS

KW - CISPLATIN-INELIGIBLE PATIENTS

KW - GEMCITABINE PLUS CISPLATIN

KW - RADICAL CYSTECTOMY

KW - OPEN-LABEL

KW - SINGLE-ARM

KW - NEOADJUVANT CHEMOTHERAPY

KW - Humans

KW - Antineoplastic Agents/therapeutic use

KW - Urinary Bladder Neoplasms/drug therapy

KW - Carcinoma, Transitional Cell/drug therapy

KW - Immunotherapy

KW - Quality of Life

U2 - 10.1080/14656566.2022.2150966

DO - 10.1080/14656566.2022.2150966

M3 - Review article

C2 - 36440477

SN - 1465-6566

VL - 24

SP - 177

EP - 195

JO - EXPERT OPINON ON PHARMACOTHERAPY

JF - EXPERT OPINON ON PHARMACOTHERAPY

IS - 2

ER -